This is the website for the Type 1 Diabetes Prevention Trial, a groundbreaking medical trial that aims to determine if type 1 diabetes can be prevented by a nasal insulin vaccine. The trial began in 2006 and is jointly funded by the National Health and Medical Research Council (NHMRC) and the Juvenile Diabetes Research Foundation (JDRF), through the Diabetes Vaccine Development Centre (DVDC).
Why nasal insulin?
The first step towards developing type 1 diabetes is the triggering of an immune reaction to the beta cells of the pancreas. This is thought to be due to environmental factors in children who are genetically susceptible. Once the immune system has reacted against the beta cells, it begins to gradually destroy them, until eventually the pancreas can no longer produce insulin. Antibodies detected by a blood test can tell us about this immune reaction to the beta cells, years before the symptoms of diabetes.
One of the components of the beta cell that the immune system reacts against is insulin itself. Initial research showed that inhalation of an insulin solution can suppress the immune system from switching into attack mode against the beta cells.
The safety of inhaled insulin was tested and proven in a previous human trial, called INIT I (Intranasal Insulin Trial I). The current trial aims to prevent the development of type 1 diabetes in children and young adults who already have at least two antibodies that cause diabetes in their blood.
You can help prevent type 1 diabetes
Type 1 diabetes effects people of all ages and evidence shows that genetics is one of the factors that determines if someone might develop diabetes. This trial identifies relatives of people with type 1 diabetes who are at high risk of developing the disease themselves. It aims to prevent type 1 diabetes in these relatives, with the use of a nasal spray vaccine. In order to find one suitable participant we need to screen around 50 people, so we are asking all relatives of people with diabetes to come forward and be tested.